Reduction of Hepatotoxicity Induced by DoxorubicinDorsaf Bengaied1,2,3*, Antonio Ribeiro4, Mohamed Amri3, Daniel Scherman1 and Philippe Arnaud1,2
1Department of Pharmacy, Chemical, Genetic and Imaging Pharmacology Laboratory, Chimie ParisTech, Paris Descartes University, Sorbonne Paris Cite, INSERM U1022, CNRS UMR8151, 4 Avenue de l’Observatoire, Paris 75006, France
- *Corresponding Author:
- Dorsaf Bengaied
Chemical, Genetic and Imaging Pharmacology Laboratory
Faculty of Pharmacy, Chimie ParisTech, Paris Descartes University
Sorbonne Paris Cite, INSERM U1022, CNRS UMR8151
4 Avenue de l’Observatoire, Paris 75006, France
E-mail: [email protected]
Received Date: April 14, 2017; Accepted Date: May 22, 2017; Published Date: May 30, 2017
Citation: Bengaied D, Ribeiro A, Amri M, Scherman D, Arnaud P (2017) Reduction of Hepatotoxicity Induced by Doxorubicin. J Integr Oncol 6:193. doi:10.4172/2329-6771.1000193
Copyright: © 2017 Bengaied D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Doxorubicin (DOX) has been used in the treatment of variety of cancers but its administration is limited by a dosedependent toxicity. Its cytotoxic effects on malignant cells have shown an increase in the risk of cardiotoxicity, hepatoxicity, renal insufisance. Antioxydants have been explored for both their cancer preventive properties and chemodulatory of DOX toxicity. Resveratrol (RSV) is a polyphenolic constituent of several dietary mainly of grapes and wine origin recently its anticancer potential has been extensively explored, revealing its anti-proliferative effect on different cancer cell lines, both in vitro and in vivo. RSV is also known to have modulatory effects on cell apoptosis, migration and growth via various signaling pathways. Though, RSV possesses great medicinal value, its applications as a therapeutic drug is limited. Problems like low oral bioavailability and poor aqueous solubility make RSV an unreliable candidate for therapeutic purposes. Additionally, the rapid gastrointestinal digestion of RSV is also a major barrier for its clinical translation. Hence, to overcome these disadvantages RSV-based nanodelivery systems have been considered in recent times. Nanodelivery systems of RSV have shown promising results in its uptake by the epithelial system as well as enhanced delivery to the target site. Herein we have tried to bring new new insights into the molecular mechanisms of DOX toxicity with respect to DNA damage, free radicals and whether RSV can be a playmaker as chemodulatory of DOx.